1. |
Chen M, Jiang H, Zhang J, et al. Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study[J]. Acta Ophthalmol, 2017, 95(6): 613-618. DOI: 10.1111/aos.13333.
|
2. |
Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification[J]. Ophthalmol Clin North Am, 2005, 18(1): 41-53. DOI: 10.1016/j.ohc.2004.11.003.
|
3. |
Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success[J]. Ophthalmology, 2006, 113(12): 2276-2280. DOI: 10.1016/j.ophtha.2006.06.018.
|
4. |
季迅达, 李家恺, 赵军阳, 等. 眼内晚期视网膜母细胞瘤静脉化学治疗失败后行眼动脉介入化学治疗的疗效观察[J]. 中华眼底病杂志, 2015, 31(6): 556-559. DOI: 10.3760/cma.j.issn.1005-1015.2015.06.011.Ji XD, Li JK, Zhao JY, et al. Efficacy of intra-arterial chemotherapy for advanced retinoblastoma after failure of intravenous chemotherapy[J]. Chin J Ocul Fundus Dis, 2015, 31(6): 556-559. DOI: 10.3760/cma.j.issn.1005-1015.2015.06.011.
|
5. |
Shields CL, Palamar M, Sharma P, et al. Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors[J]. Arch Ophthalmol, 2009, 127(3): 282-290. DOI: 10.1001/archophthalmol.2008.626.
|
6. |
Gündüz AK, Mirzayev I, Dinçaslan H, et al. Recurrence and new tumor development after frontline intravenous chemotherapy for retinoblastoma risk factors and treatment results[J]. Eur J Ophthalmol, 2022, 32(3): 1795-1803. DOI: 10.1177/11206721211023311.
|
7. |
魏文斌, 周楠. 重视视网膜母细胞瘤的规范化治疗, 提升视网膜母细胞瘤的治疗水平[J]. 中华眼底病杂志, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.Wei WB, Zhou N. Attach importance to standardized treatment of retinoblastoma to improve its treatment outcome[J]. Chin J Ocul Fundus Dis, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.
|
8. |
Kaliki S, Srinivasan V, Gupta A, et al. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study[J]. Ophthalmology, 2015, 122(6): 1165-1172. DOI: 10.1016/j.ophtha.2015.01.018.
|
9. |
Fang X, Chen J, Wang Y, et al. RB1 germline mutation spectrum and clinical features in patients with unilateral retinoblastomas[J]. Ophthalmic Genet, 2021, 42(5): 593-599. DOI: 10.1080/13816810.2021.1946703.
|
10. |
Zou Y, Li J, Hua P, et al. Spectrum of germline mutations in RB1 in Chinese patients with retinoblastoma: application of targeted next-generation sequencing[J]. Mol Vis, 2021, 27: 1-16.
|
11. |
程湧, 贾忠旭, 赵明威, 等. 视网膜母细胞瘤综合治疗的回顾性临床研究[J]. 中华眼底病杂志, 2020, 36(6): 419-424. DOI: 10.3760/cma.j.cn511434-20200205-00040.Chen Y, Jia ZX, Zhao MW, et al. Retrospective clinical study on the comprehensive treatment of retinoblastoma[J]. Chin J Ocul Fundus Dis, 2020, 36(6): 419-424. DOI: 10.3760/cma.j.cn511434-20200205-00040.
|
12. |
Zhou C, Wen X, Ding Y, et al. Eye-preserving therapies for advanced retinoblastoma: a multicenter cohort of 1678 patients in China[J]. Ophthalmology, 2022, 129(2): 209-219. DOI: 10.1016/j.ophtha.2021.09.002.
|
13. |
Fabian ID, Stacey AW, Johnson KP, et al. Primary intravenous chemotherapy for group D retinoblastoma: a 13-year retrospective analysis[J]. Br J Ophthalmol, 2017, 101(1): 82-88. DOI: 10.1136/bjophthalmol-2016-309710.
|
14. |
Abramson DH, Daniels AB, Marr BP, et al. Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma[J/OL]. PLoS One, 2016, 11(1): e0146582[2016-01-12]. https://pubmed.ncbi.nlm.nih.gov/26756643/. DOI: 10.1371/journal.pone.0146582.
|
15. |
Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience[J]. Arch Ophthalmol, 2011, 129(6): 732-737. DOI: 10.1001/archophthalmol.2011.5.
|
16. |
Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma[J]. Ophthalmology, 2014, 121(7): 1453-1460. DOI: 10.1016/j.ophtha.2014.01.026.
|
17. |
Munier FL, Mosimann P, Puccinelli F, et al. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment[J]. Br J Ophthalmol, 2017, 101(8): 1086-1093. DOI: 10.1136/bjophthalmol-2016-309298.
|
18. |
Munier FL, Mosimann P, Puccinelli F, et al. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma[J]. Br J Ophthalmol, 2017, 101(8): 1086-1093. DOI: 10.1016/j.ophtha.2011.08.045.
|
19. |
Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications[J]. Arch Ophthalmol, 2011, 129(11): 1407-1415. DOI: 10.1001/archophthalmol.2011.151.
|
20. |
Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds[J]. Arch Ophthalmol, 2011, 129(11): 1399-1406. DOI: 10.1001/archophthalmol.2011.150.
|
21. |
Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results[J]. Br J Ophthalmol, 2012, 96(4): 499-502. DOI: 10.1136/bjophthalmol-2011-300498.
|
22. |
Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications[J]. Br J Ophthalmol, 2012, 96(8): 1078-1083. DOI: 10.1136/bjophthalmol-2011-301450.
|
23. |
Shields CL, Douglass AM, Beggache M, et al. Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture[J]. Retina, 2016, 36(6): 1184-1190. DOI: 10.1097/iae.0000000000000903.
|